<DOC>
	<DOC>NCT01335607</DOC>
	<brief_summary>The purpose of this study is to: - Assess the relative bioavailability of 2 oral formulations of samatasvir (capsule and tablet prototype test formulation) - Compare the amount of study drug that is in the blood after taking either the capsule form of the drug or the tablet form of the drug while fasting. - Determine the amount of study drug that is in the blood after eating a meal. - Evaluate the safety of the tablet form of samatasvir in healthy people.</brief_summary>
	<brief_title>A Open-label Study to Evaluate the Relative Bioavailability of Samatasvir (IDX184) and Food Effect in Healthy Male Participants (MK-2355-006)</brief_title>
	<detailed_description>Each participant will receive each of the formulations in a crossover design. Part A Periods 1 and 2: Participants will receive either samatasvir capsules or tablets according to randomization under fasting conditions on Days 1 and 8. Part A Period 3: All participants will receive samatasvir tablets under fed conditons on Day 15. Each dose will be separated by a 7-day wash-out period. Part B: All participants will receive samatasvir capsules under fed conditons on Day 1.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Must be a healthy male with body mass index (BMI) between 18 and 35 kg/m Must agree to use an acceptable doublebarrier method of birth control. Must provide written informed consent after the study has been fully explained. History of clinically significant diseases, as determined by the investigator. Safety laboratory abnormalities at screening which are clinically significant. Positive screening test for hepatitis B virus, hepatitis C virus or human immunodeficiency virus (HIV). Use of chronic prescription medications within 3 months, acute prescription medications within 14 days, or systemic overthecounter (OTC) medications within 7 days of the starting the study. Current abuse of alcohol or illicit drugs, or history of alcohol or illicit drug abuse within the preceding two years.</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C Virus</keyword>
</DOC>